Tenders Are Invited For Pharmaceutical Products - Contract Announcement - Conclusion Of Non-Exclusive Discou ... in Germany

Work Detail

Pharmaceutical Products - Contract Announcement - Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Medicinal Products With The Active Ingredient Zidovudine/Lamivudine/Abacavir. Gwq Serviceplus Ag Intends To Enter Into Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V On The Above. To Close The Active Ingredient. This Contract Can Be Terminated At Any Time During The Contract Period, All Interested Companies Will Join Under The Same Conditions (Approval Model). The Gwq Assumes That This Procedure Is Based On A Lack Of A Selection Decision And Therefore The Possibility Of Non-Discriminatory Access Of All Pharmaceutical Companies Do Not Fall Within The Scope Of Antitrust Procurement Law Falls. The Contract Documents, The Participating Health Insurance Companies And Their Sales As Well The Dates For Reporting The Contract Are On The Gwq Serviceplus Procurement Portal Ag Can Be Viewed And Downloaded At Http://Vergabeportal.Gwq-Serviceplus.De. This Interim Agreement Stands Until Exclusive Contracts Start Open To All Market Participants To Join. Upon Receipt Of The Signed Contracts / Declaration And Evidence As Of December 10Th, 2023 Can Be Reported For The First Time On January 1St, 2024 Will Be Realized. The Following Documents Must Be Submitted: - Signed Contract In Duplicate; - Proof Of Drug Approval By Means Of An Extract From The Public Part Of The Amice Database; - Pzn List (Appendix 2) - Signed Self-Declaration (Appendix 3) - Declaration On The Regulation (Appendix 5) - Self-Disclosure On Sustainability (Appendix 6)

Contact Information